此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

JNJ-68284528,一种针对多发性骨髓瘤患者 B 细胞成熟抗原 (BCMA) 的嵌合抗原受体 T 细胞 (CAR-T) 疗法的研究 (CARTITUDE-2)

2026年11月2日 更新者:Janssen Research & Development, LLC

JNJ-68284528 的 2 期多队列开放标签研究,一种针对多发性骨髓瘤患者 BCMA 的嵌合抗原受体 T 细胞 (CAR-T) 疗法

The purpose of this study is to evaluate the overall minimal residual disease (MRD) negative rate of participants who receive JNJ-68284528.

研究概览

研究类型

介入性

注册 (实际的)

208

阶段

  • 阶段2

扩展访问

可用的 查看扩展访问记录。

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

      • Ramat Gan、以色列、52621
        • Sheba Medical Center Tel Hashomer
      • Tel Aviv、以色列、64239
        • Tel Aviv Sourasky Medical Center
      • Hamburg、德国、20246
        • Universitaetsklinikum Hamburg Eppendorf
      • Würzburg、德国、97080
        • Universitatsklinikum Wurzburg
      • Ghent、比利时、9000
        • UZ Gent
      • Leuven、比利时、3000
        • UZ Leuven
      • Riyadh、沙特阿拉伯、11211
        • King Faisal Specialist Hospital & Research Center
      • Lille、法国、59037
        • CHRU de Lille Hopital Claude Huriez
      • Nantes、法国、44093
        • C.H.U. Hotel Dieu - France
      • Paris、法国、75475
        • Hopital Saint Louis
    • California
      • San Diego、California、美国、92037
        • University Of California San Diego
      • San Francisco、California、美国、94143
        • University of California San Francisco
    • Connecticut
      • New Haven、Connecticut、美国、06510
        • Yale University School Of Medicine
    • Florida
      • Tampa、Florida、美国、33612
        • Moffitt Cancer Center
    • Georgia
      • Atlanta、Georgia、美国、30322
        • Emory University
    • Illinois
      • Chicago、Illinois、美国、60611
        • Northwestern University
      • Chicago、Illinois、美国、60637
        • University of Chicago
    • Indiana
      • Indianapolis、Indiana、美国、46202
        • Indiana University
    • Iowa
      • Iowa City、Iowa、美国、52242
        • University of Iowa Hospitals and Clinics
    • Kansas
      • Westwood、Kansas、美国、66205
        • University of Kansas Cancer Center
    • Kentucky
      • Louisville、Kentucky、美国、40207
        • Norton Cancer Institute
    • Massachusetts
      • Boston、Massachusetts、美国、02115
        • Dana Farber Cancer Institute
    • Michigan
      • Detroit、Michigan、美国、48201
        • Barbara Ann Karmanos Cancer Institute
    • Minnesota
      • Rochester、Minnesota、美国、55905
        • Mayo Clinic Rochester
    • Missouri
      • St Louis、Missouri、美国、63108
        • Washington University School Of Medicine
    • New Jersey
      • Hackensack、New Jersey、美国、07601
        • Hackensack University Medical Center
      • New Brunswick、New Jersey、美国、08903
        • Rutgers Cancer Institute of New Jersey
    • New York
      • Buffalo、New York、美国、14263
        • Roswell Park Cancer Institute
      • New York、New York、美国、10065
        • Memorial Sloan-Kettering Cancer Center
      • New York、New York、美国、10029
        • Mount Sinai Medical Center
      • The Bronx、New York、美国、10467
        • Montefiore Medical Center
    • North Carolina
      • Charlotte、North Carolina、美国、28204
        • Levine Cancer Institute, Carolinas HealthCare System
    • Ohio
      • Cleveland、Ohio、美国、44195
        • Cleveland Clinic
    • Oregon
      • Portland、Oregon、美国、97239
        • Oregon Health And Science University
    • Pennsylvania
      • Philadelphia、Pennsylvania、美国、19104
        • University of Pennsylvania
      • Philadelphia、Pennsylvania、美国、19107
        • Thomas Jefferson University
      • Pittsburgh、Pennsylvania、美国、15232
        • University of Pittsburgh
    • Texas
      • Dallas、Texas、美国、75390
        • University of Texas Southwestern Medical Center
    • Utah
      • Salt Lake City、Utah、美国、84112
        • University of Utah
    • Virginia
      • Charlottesville、Virginia、美国、22908
        • University of Virginia
      • Richmond、Virginia、美国、23298
        • Virginia Commonwealth University - Massey Cancer Center
    • Washington
      • Seattle、Washington、美国、98109
        • Fred Hutchinson Cancer Center
    • Wisconsin
      • Madison、Wisconsin、美国、53705
        • University of Wisconsin Carbone Cancer Center
      • Amsterdam、荷兰、1081 HV
        • VU Medisch Centrum
      • Groningen、荷兰、9713 GZ
        • University Medical Center Groningen
      • Pamplona、西班牙、31008
        • Clinica Univ. de Navarra
      • Salamanca、西班牙、37007
        • Hosp Clinico Univ de Salamanca

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Cohort A: Received a minimum of 1 to a maximum of 3 prior lines of therapy including a proteasome inhibitor (PI) and immunomodulatory therapy (IMiD), and lenalidomide refractory per International Myeloma Working Group (IMWG) guidelines
  • Cohort B: Received one line of prior therapy including a PI and an IMiD, and disease progression per IMWG criteria less than or equal to (<=) 12 months after treatment with autologous stem cell transplantation (ASCT) or <=12 months from the start of anti-myeloma therapy for participants who have not had an ASCT
  • Cohort C: Previously treated with a PI, an IMiD, an anti-CD38 monoclonal antibody and B-cell maturation antigen (BCMA)-directed therapy
  • Cohort D: Newly diagnosed multiple myeloma per IMWG with a history of 4 to 8 total cycles of initial therapy, including induction, high-dose therapy, and ASCT with or without consolidation
  • Cohort E: Have newly diagnosed multiple myeloma without prior therapy (one cycle of prior therapy before enrollment is acceptable) and classified as high risk defined as either: 1) International Staging System (ISS) stage III criteria, Beta 2 microglobulin greater than or equal to (>=) 5.5 milligrams per liter (mg/L) (via local or central laboratory assessment) or 2) high risk cytogenetic features del(17/17p), t (14;16), t(14;20), 1q amplification (at least 4 total copies) in at least 20 percent (%) of the total plasma cell population
  • Cohort F:
  • Participant must have a documented efficacy response of very good partial response (VGPR) or better, without progressive disease prior to enrollment, as assessed per IMWG 2016 criteria
  • Received initial therapy as specified below. The dose/schedule of cycles administered will be as per standard of care. It is acceptable for up to 1 cycle of the protocol-specified regimens to be missing one of the listed agents (example, held due to toxicity). Acceptable combinations include: At least 5 to 8 cycles of initial therapy with daratumumab, bortezomib, lenalidomide and dexamethasone (D-VRd). The dose/schedule of cycles administered will be as per standard of care or; at least 4 to 8 cycles of initial therapy with daratumumab, lenalidomide and dexamethasone (D-Rd) or; at least 4 to 8 cycles of initial therapy with a carfilzomib-based triplet or quadruplet regimen
  • For US sites only: Cohort G: Not considered for high-dose chemotherapy with autologous stem cell transplantation (ASCT) due to: a) Ineligibility due to advanced age; or b) Ineligibility due to presence of comorbid condition(s) likely to have a negative impact on tolerability of high-dose chemotherapy with ASCT; or c) Subject refusal of high-dose chemotherapy with ASCT as initial treatment
  • Cohorts A, B, C, E and Cohort G (for US sites only):
  • Serum monoclonal paraprotein (M-protein) level greater than or equal to (>=) 1.0 gram per deciliter (g/dL) or urine M-protein level >=200 milligrams (mg)/24 hours
  • Light chain multiple myeloma in whom only measurable disease is by serum free light chain (FLC) levels in the serum: Serum immunoglobulin FLC >=10 mg/dL and abnormal serum immunoglobulin kappa lambda FLC ratio
  • Cohort A: For participants with neither serum nor urine measurable disease, baseline positron emission tomography/ computed tomography (PET/CT) or whole -body magnetic resonance imaging (MRI) may be used to satisfy the measurable disease criteria. A minimum of one lesion with a bi-dimensional measurement of at least 1 centimeter (cm)*1 cm is required
  • Cohorts B, C: For participants with neither serum nor urine measurable disease, baseline positron emission tomography/ computed tomography (PET/CT) or whole body magnetic resonance imaging (MRI) may be used to satisfy the measurable disease criteria
  • Cohorts A, B, C, D, E, F and Cohort G (for US sites only): Eastern Cooperative Oncology Group (ECOG) performance status grade of 0 or 1

Exclusion Criteria:

  • Cohorts A, B, D, F: Any therapy that is targeted to BCMA
  • Cohorts A, B, C, D, F: Prior treatment with chimeric antigen receptor T (CAR-T) therapy directed at any target
  • Cohorts A, B, C, D, F:
  • Ongoing toxicity from previous anticancer therapy must resolve to baseline levels or to Grade 1 or less except for alopecia or peripheral neuropathy
  • Received a cumulative dose of corticosteroids equivalent to >=70 mg of prednisone within the 7 days (Cohort A, B, C, F) or 14 days (Cohort D) prior to apheresis
  • Serious underlying medical condition, such as (a) evidence of active viral or bacterial infection requiring systemic antimicrobial therapy, or uncontrolled systemic fungal infection; (b) active autoimmune disease or a history of autoimmune disease within 3 years; (c) overt clinical evidence of dementia or altered mental status; (d) any history of Parkinson's disease or other neurodegenerative disorder
  • Cohorts A, B, C, D, E, F: Known active, or prior history of central nervous system (CNS) involvement or exhibits clinical signs of meningeal involvement of multiple myeloma
  • Cohort F and Cohort G (for US sites only): Active malignancies (that is, progressing or requiring treatment change in the last 24 months) other than the disease being treated under study. The only allowed exceptions are: a) non-muscle invasive bladder cancer treated within the last 24 months that is considered completely cured; b) skin cancer (non-melanoma or melanoma) treated within the last 24 months that is considered completely cured; c) non-invasive cervical cancer treated within the last 24 months that is considered completely cured; d) localized prostate cancer (N0M0): with a Gleason score of greater than or equal to (=>)6, treated within the last 24 months or untreated and under surveillance, with a Gleason score of 3+4 that has been treated more than 6 months prior to full study screening and considered to have a very low risk of recurrence, or history of localized prostate cancer and receiving androgen deprivation therapy and considered to have a very low risk of recurrence, e) breast cancer: adequately treated lobular carcinoma in situ or ductal carcinoma in situ, or history of localized breast cancer and receiving antihormonal agents and considered to have a very low risk of recurrence; f) malignancy that is considered cured with minimal risk of recurrence
  • Cohort E and Cohort G (for US sites only): Frailty index of >= 2 according to Myeloma Geriatric Assessment score

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:不适用
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:JNJ-68284528

Single group assignment-Post lymphodepletion, JNJ-68284528 single infusion given to Part A participants: Cohort A (Progressive disease post 1-3 prior lines of therapy), Cohort B (Early relapse post front-line), Cohort C(Relapsed/refractory multiple myeloma post PI, IMiD,anti-CD38,anti-BCMA therapy), Cohort D(Less than CR post ASCT front-line therapy, some participants will receive JNJ-68284528 then lenalidomide), Cohort F(Newly diagnosed multiple myeloma [NDMM], standard risk [International Staging System Stage I/II] and post initial therapy); Cohort E(NDMM,transplant not planned, high risk disease) will first receive quadruplet induction regimen of daratumumab, bortezomib, lenalidomide and dexamethasone(D-VRd) then lymphodepletion and JNJ-68284528 then consolidation regimen of lenalidomide. Enrollment is closed for Cohorts A,B,C,D,E and F. For US sites only: Part B:Cohort G (NDMM, transplant not planned) will receive daratumumab, lenalidomide and dexamethasone followed by cilta-cel.

Participants in Cohorts A,B,C, D, E, F and Cohort G (for US sites only) will receive JNJ-68284528 intravenously.

其他名称:
  • Ciltacabtagene autoleucel (cilta-cel)

Some participants in Cohort D and all participants in Cohorts E and Cohort G (for US sites only) will also receive lenalidomide capsules orally.

Participants in Cohorts E and Cohort G (for US sites only) will also receive daratumumab subcutaneous (SC) injection.

Participants in Cohorts E will also receive bortezomib subcutaneously.

Participants in Cohorts E and Cohort G (for US sites only) will also receive dexamethasone orally or intravenously.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Cohorts A, B, C, D, E, and F: Percentage of Participants with Negative Minimal Residual Disease (MRD)
大体时间:At least 1 year after JNJ-68284528 infusion on Day 1

MRD negative rate is the percentage of participants who achieve MRD negative status by evaluation of bone marrow aspirate as defined by the International Myeloma Working Group (IMWG) criteria.

At least 1 year after JNJ-68284528 infusion on Day 1
For US sites only: Cohort G: Percentage of Participants with Sustained MRD Negative Complete Response (CR)
大体时间:At least 1 year after JNJ-68284528 infusion on Day 1

Sustained MRD-negative CR is defined as participants with CR or better who sustain MRD-negative status, as determined by next-generation sequencing (NGS) or next generation flowcytometry (NGF) with sensitivity of 10^-5, for at least 12 months without any examination showing MRD positive status or progressive disease in between.

At least 1 year after JNJ-68284528 infusion on Day 1

次要结果测量

结果测量
措施说明
大体时间
Overall Response Rate (ORR)
大体时间:Up to 8 years and 10 months

ORR is defined as the percentage of participants who achieve a partial response (PR) or better according to the IMWG criteria.

Up to 8 years and 10 months
Cohorts A, B, C, D, E, and F: VGPR or Better Rate
大体时间:Up to 8 years and 10 months

The VGPR or better rate (stringent complete responses [sCR] + complete response [CR] + VGPR), defined as the percentage of participants achieving VGPR or better response according to IMWG criteria during or after the study treatment.

Up to 8 years and 10 months
Cohorts A, B, C, D, E, and F: Clinical Benefit Rate (CBR)
大体时间:Up to 8 years and 10 months

CBR is defined as the percentage of participants who achieve ORR (sCR + CR + VGPR + PR) + minimal response (MR) according to the IMWG criteria.

Up to 8 years and 10 months
Duration of Response (DOR)
大体时间:Up to 8 years and 10 months

DOR will be calculated among responders from the date of initial documentation of a response (PR or better) to the date of first documented evidence of progressive disease according to the IMWG criteria.

Up to 8 years and 10 months
Time to Response (TTR)
大体时间:Up to 8 years and 10 months

TTR is defined as the time from the date of the initial infusion of JNJ-68284528 and the first efficacy evaluation that the participant has met all criteria for PR or better.

Up to 8 years and 10 months
Cohorts A, B, C, D, E, and F: MRD Negative Rate at 12 Months for Participants who Achieve a Complete Response (CR)
大体时间:12 months

MRD negative rate at 12 months for participants who achieved a complete response (CR) is defined as the percentage of participants who are MRD negative by bone marrow aspirate and meet the IMWG criteria for CR at 12 months after initial dose of JNJ-68284528 and before disease progression or starting subsequent therapy including retreatment of JNJ-68284528.

12 months
Time to MRD Negativity
大体时间:Up to 8 years and 10 months

Time to MRD negativity will be calculated in participants who are MRD negative by bone marrow aspirate from the date of the initial infusion of JNJ-68284528 to the initial date of reaching the MRD negative status.

Up to 8 years and 10 months
Duration of MRD Negativity
大体时间:Up to 8 years and 10 months

Duration of MRD negativity will be calculated among participants who are MRD negative by bone marrow aspirate from the date of initial MRD negativity to the date when MRD is detected at the same threshold (10^-5).

Up to 8 years and 10 months
Cohorts A, B, C, D, E, and F: MRD Negative Rate Across Clinical Response
大体时间:Up to 8 years and 10 months

MRD negative rate across clinical response groups will be assessed for all participants who achieved a complete response (CR) or stringent complete response (sCR) or very good partial response (VGPR) according to the IMWG criteria during or after the study treatment. MRD negative rate is defined as the percentage of participants who have negative MRD by bone marrow aspirate at any timepoint.

Up to 8 years and 10 months
Number of Participants with Adverse Events by Severity
大体时间:Up to 8 years and 10 months

An assessment of severity grade will be made according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), with the exception of cytokine release syndrome (CRS), and immune effector cell-associated neurotoxicity syndrome (ICANS). CRS and ICANS will be evaluated according to the American Society for Transplantation and Cellular Therapy (ASTCT) consensus grading.

Up to 8 years and 10 months
Number of Participants with Adverse Events (AE) as a Measure of Safety and Tolerability
大体时间:Up to 8 years and 10 months

An AE is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product.

Up to 8 years and 10 months
Number of Participants with Laboratory Abnormalities
大体时间:Up to 8 years and 10 months

Number of participants with laboratory abnormalities will be reported.

Up to 8 years and 10 months
Number of Participants with Vital Signs Abnormalities
大体时间:Up to 8 years and 10 months

Number of participants with vital signs abnormalities will be reported.

Up to 8 years and 10 months
Cohorts A, B, C, D, E, and F: Levels of B-Cell Maturation Antigen (BCMA) Expressing Cells and Soluble BCMA
大体时间:Up to 1 year

Levels of expression of BCMA-expressing plasma cells in the bone marrow as well as the level of soluble BCMA in blood will be reported.

Up to 1 year
Cohorts A, B, C, D, E, and F: Systemic Inflammatory Cytokine Concentrations
大体时间:Up to 1 year

Blood cytokine concentrations (Interleukin [IL]-6, IL-15, IL-10, and Interferon [IFN-gamma]) will be measured for biomarker assessment.

Up to 1 year
Cohorts A, B, C, D, E, and F: Levels of JNJ-68284528 T Cell Expansion (proliferation), and Persistence
大体时间:Up to 1 year

Levels of JNJ-68284528 T cell expansion (proliferation), and persistence via monitoring CAR-T positive cell counts and CAR transgene level will be reported.

Up to 1 year
Cohorts A, B, C, D, E, and F: Number of Participants with Anti-JNJ-68284528 Antibodies
大体时间:Up to 1 year

Number of participants exhibiting anti-drug antibodies for JNJ-68284528 will be reported.

Up to 1 year
For US sites only: Cohort G: Percentage of Participants with Complete Response (CR) or Better
大体时间:Up to 8 years and 10 months

CR or better is defined as the percentage of participants achieving CR or sCR prior to subsequent antimyeloma therapy in accordance with the IMWG criteria during or after the study treatment.

Up to 8 years and 10 months
For US sites only: Cohort G: Percentage of Participants with MRD-negative CR or sCR
大体时间:Up to 8 years and 10 months

MRD-negative CR/sCR is defined as the percentage of participants who achieve MRD-negative status, as determined by NGS/NGF with sensitivity of 10^-5, at any time after enrollment and prior to progressive disease or subsequent antimyeloma therapy and who achieve CR/sCR or better.

Up to 8 years and 10 months
For US sites only: Cohort G: Progression-free Survival on Next-line Therapy (PFS2)
大体时间:Up to 8 years and 10 months

PFS2 is defined as the time interval between the start of study treatment and date of event, which is defined as death from any cause or PD as assessed by investigator that starts after the next line of therapy, whichever occurs first.

Up to 8 years and 10 months
For US sites only: Cohort G: Overall Survival (OS)
大体时间:Up to 8 years and 10 months

OS is defined as the time from the start of study treatment to the date of the participant's death.

Up to 8 years and 10 months
For US sites only: Cohort G: Progression-free Survival (PFS)
大体时间:Up to 8 years and 10 months

PFS is defined as the time from the start of study treatment to the date of first documented disease progression, as defined in the IMWG criteria, or death due to any cause, whichever occurs first.

Up to 8 years and 10 months
For US sites only: Cohort G: Number of Participants with Measurable Replication Competent Lentivirus (RCL) in Whole Blood
大体时间:Up to 8 years and 10 months

Number of participants with measurable RCL in whole blood will be reported.

Up to 8 years and 10 months
For US sites only: Cohort G: Time to Subsequent Anti-Myeloma Therapy
大体时间:Up to 8 years and 10 months

Time to subsequent anti-myeloma treatment is defined as the time from start of study treatment to the start of subsequent anti-myeloma treatment.

Up to 8 years and 10 months

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 研究主任:Janssen Research & Development, LLC Clinical Trial、Janssen Research & Development, LLC

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

有用的网址

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2019年11月7日

初级完成 (估计的)

2027年2月26日

研究完成 (估计的)

2028年8月25日

研究注册日期

首次提交

2019年10月18日

首先提交符合 QC 标准的

2019年10月18日

首次发布 (实际的)

2019年10月21日

研究记录更新

最后更新发布 (实际的)

2026年11月3日

上次提交的符合 QC 标准的更新

2026年11月2日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

是的

IPD 计划说明

The data sharing policy of Johnson & Johnson Innovative Medicine is available at www.innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅